Curevac N.V. (CVAC)

Apr 10, 2025, 12:59 PM EDT - 4 weeks ago

CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript

Apr 10, 2025, 7:30 AM EDT - 4 weeks ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Apr 8, 2025, 7:25 AM EDT - 5 weeks ago

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

Apr 7, 2025, 7:15 AM EDT - 5 weeks ago

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Mar 28, 2025, 12:45 PM EDT - 6 weeks ago

CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit

BNTX

Mar 28, 2025, 8:58 AM EDT - 6 weeks ago

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps

Mar 27, 2025, 6:22 PM EDT - 6 weeks ago

European Patent Office declares CureVac mRNA patent valid

Mar 27, 2025, 4:30 PM EDT - 6 weeks ago

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

Feb 18, 2025, 7:15 AM EST - 3 months ago

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

Jan 8, 2025, 4:55 PM EST - 4 months ago

CureVac: Latest GBM Data Bodes Well For Next Program Check Point

Nov 12, 2024, 3:08 PM EST - 6 months ago

CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:20 AM EST - 6 months ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

Nov 7, 2024, 7:30 AM EST - 6 months ago

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

Nov 4, 2024, 7:20 AM EST - 6 months ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

Nov 4, 2024, 7:15 AM EST - 6 months ago

CureVac to Present at the 12th International mRNA Health Conference

Oct 28, 2024, 8:10 AM EDT - 7 months ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 8, 2024, 5:50 AM EDT - 7 months ago

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

BNTX PFE

Sep 13, 2024, 8:15 AM EDT - 8 months ago

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Sep 12, 2024, 7:15 AM EDT - 8 months ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

Sep 9, 2024, 7:15 AM EDT - 8 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Aug 15, 2024, 7:30 AM EDT - 9 months ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

Aug 15, 2024, 7:20 AM EDT - 9 months ago

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

Aug 15, 2024, 7:15 AM EDT - 9 months ago

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

Jul 11, 2024, 7:15 AM EDT - 10 months ago

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

Jul 11, 2024, 7:00 AM EDT - 10 months ago

Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

Jul 3, 2024, 10:18 AM EDT - 11 months ago

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

GSK

Jul 3, 2024, 7:53 AM EDT - 11 months ago

CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines

GSK

Jul 3, 2024, 2:40 AM EDT - 11 months ago

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK

Jul 3, 2024, 2:40 AM EDT - 11 months ago

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

Jul 3, 2024, 2:26 AM EDT - 11 months ago

GSK buys full rights to make COVID, influenza vaccines from CureVac

GSK

Jun 24, 2024, 4:20 PM EDT - 11 months ago

CureVac Announces Voting Results of General Meeting

Apr 24, 2024, 3:12 PM EDT - 1 year ago

CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript

Apr 24, 2024, 7:30 AM EDT - 1 year ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Apr 24, 2024, 7:20 AM EDT - 1 year ago

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Apr 24, 2024, 7:20 AM EDT - 1 year ago

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Apr 18, 2024, 7:15 AM EDT - 1 year ago

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

Apr 16, 2024, 7:15 AM EDT - 1 year ago

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

Apr 4, 2024, 7:15 AM EDT - 1 year ago

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

Jan 5, 2024, 7:59 AM EST - 1 year ago

CureVac stock gains as COVID vaccine candidates show promise

Jan 5, 2024, 7:30 AM EST - 1 year ago

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

Dec 19, 2023, 9:35 AM EST - 1 year ago

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Nov 14, 2023, 3:15 PM EST - 1 year ago

CureVac N.V. (CVAC) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 7:30 AM EST - 1 year ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

Nov 1, 2023, 8:15 AM EDT - 1 year ago

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

Sep 28, 2023, 7:15 AM EDT - 1 year ago

CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany

Sep 12, 2023, 8:05 AM EDT - 1 year ago

CureVac signals progress on mRNA flu vaccine

Sep 12, 2023, 7:15 AM EDT - 1 year ago

CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage

Aug 17, 2023, 7:15 AM EDT - 1 year ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

Aug 1, 2023, 7:15 AM EDT - 1 year ago

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

Jul 24, 2023, 9:51 AM EDT - 1 year ago

CureVac's CVGBM Trial: Promising Results Progress Pipeline